Foundayo (Orforglipron)

Where it stands

Foundayo (orforglipron) has a positive CHMP opinion in the EU, dated 15 October 2026. The applicant is Eli Lilly Nederland B.V. The records show no EC approval date yet, so the product is not authorised in the EU at this point. The recorded status is 'Opinion'.

The recorded indication is the treatment of obesity and type 2 diabetes mellitus in adults. The therapeutic areas listed are obesity, overweight and diabetes mellitus.

In the US, the FDA approved Foundayo (orforglipron calcium) on 1 April 2026 under NDA220934. The records classify it as a new molecular entity and a tablet, and the sponsor is Eli Lilly and Co. The CHMP opinion came roughly six and a half months after the US approval.

Regulatory pathway and designations

The records show no designations for this product in the EU. That means no orphan, PRIME or similar status is recorded. The records also do not say whether accelerated assessment, conditional marketing authorisation or exceptional circumstances apply, so none should be assumed.

A CHMP positive opinion is the scientific recommendation of the EMA committee. It is not itself a marketing authorisation. The European Commission issues the legally binding decision, which applies across the EU/EEA.

The records give an expected EC decision date of 21 December 2026. This is an estimate, calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. It is not an official date, and the actual decision could fall earlier or later.

Safety and pharmacovigilance

The records contain no safety data, risk management plan details, labelling warnings or post-authorisation commitments for Foundayo, so no safety assessment can be made from them.

What to watch

The main near-term event is the EC decision. The records estimate it for around 21 December 2026, but this is not an official date. Confirmation of the actual decision will mark the start of EU authorised status.

Once published, the CHMP summary of opinion and the product information will show the final indication wording, any conditions or additional monitoring, and the safety content. The records do not include these. The US label wording is also not in the records, so the EU and US indications cannot be compared from this data.

Launch timing, pricing, reimbursement and any further regional approvals are not covered by the records and should not be inferred from the opinion alone.